| View |
|
BRP-100-11
|
Epoetin Alfa
|
None
|
4000 IU/mL
|
Solution for Injection (IV/SC)
|
Antianemic Preparations
|
Shenyang Sunshine Pharmaceutical Co., Ltd.
|
China
|
CLIDP Conversion
|
15 February 2024
|
14 December 2026
|
| View |
|
DR-XY29289
|
Phenylephrine Hydrochloride + Chlorphenamine Maleate
|
Bronchofen
|
5 mg/1 mg per 5 mL
|
Syrup
|
Nasal Decongestant/Antihistamine
|
Lloyd Laboratories, Inc
|
Philippines
|
Automatic Renewal
|
17 January 2024
|
05 January 2029
|
| View |
|
DR-XY43127
|
Sildenafil (as Citrate)
|
Hydenex
|
50 mg
|
Tablet
|
Phosphodiesterase Type 5 Inhibitor
|
Compact Pharmaceuticals Corp
|
Philippines
|
Renewal
|
15 March 2024
|
20 February 2029
|
| View |
|
DR-XY43344
|
Regorafenib
|
Stivarga
|
40 mg
|
Film-Coated Tablet
|
Antineoplastic
|
Bayer AG
|
Germany
|
Automatic Renewal (E-AR)
|
01 March 2024
|
08 April 2029
|
| View |
|
DRP-14046-02
|
Cetirizine (as hydrochloride)
|
Arizt
|
10 mg
|
Film Coated Tablet
|
Antihistamine (Piperazine Derivative)
|
Magbro Healthcare Pvt. Ltd
|
India
|
CLIDP Conversion
|
12 February 2024
|
08 June 2028
|
| View |
|
DRP-10199-12
|
Trimetazidine hydrochloride
|
Trimedial
|
35 mg
|
Modified-Release Tablet
|
Anti-angina
|
Zim Laboratories Limited
|
India
|
CLIDP Conversion
|
31 January 2024
|
04 August 2026
|
| View |
|
DRP-10199-13
|
Trimetazidine hydrochloride
|
Trimevita
|
35 mg
|
Modified-Release Tablet
|
Anti-angina
|
Zim Laboratories Limited
|
India
|
CLIDP Conversion
|
01 March 2024
|
04 August 2026
|
| View |
|
BRP-136
|
Heparin Sodium
|
Nuparin
|
1000 IU/mL (5000 IU/5 mL)
|
Solution for Injection (IV/SC)
|
Antithrombotic Agents
|
Troikaa Pharmaceuticals Limited
|
India
|
-
|
07 February 2024
|
10 May 2029
|
| View |
|
DRP-10246-10
|
Ceftriaxone (as sodium)
|
Cabcef
|
1 g
|
Powder for Injection (IM/IV)
|
Antibacterial (Third-Generation Cephalosporin)
|
Theon Pharmaceuticals Limited
|
India
|
CLIDP Conversion
|
19 February 2024
|
01 October 2026
|
| View |
|
DRP-10292-01
|
Ascorbic Acid
|
Young-C OD
|
100 mg per mL
|
Syrup (Oral Drops) (Orange Flavor)
|
Vitamin
|
Enicar Pharmaceuticals Pvt. Ltd.
|
India
|
CLIDP Conversion
|
16 January 2024
|
03 September 2026
|
| View |
|
DRP-10350-01
|
Paracetamol
|
Biodol Plus
|
250 mg/5 mL
|
Oral Suspension
|
Analgesic and Antipyretic
|
Ratnatris Pharmaceuticals Pvt. Ltd.
|
India
|
CLIDP Conversion
|
06 February 2024
|
28 October 2026
|
| View |
|
DRP-10411-01
|
Metformin hydrochloride + Sitagliptin (as phosphate monohydrate)
|
Lupigliptin Plus
|
1g /50mg
|
Film-Coated Tablet
|
Oral Hypoglycemic Agent (Biguanide) / Dipeptidyl Peptidase 4 (DPP-4 Inhibitor)
|
Lloyd Laboratories, Inc
|
Philippines
|
CLIDP Conversion
|
07 December 2022
|
28 September 2026
|
| View |
|
DRP-10411-02
|
Sitagliptin (as phosphate) + Metformin Hydrochloride
|
None
|
50 mg/1 g
|
Film-Coated Tablet
|
Combination of Oral Blood Glucose Lowering Drugs
|
Lloyd Laboratories, Inc
|
Philippines
|
CLIDP Conversion
|
19 January 2024
|
28 September 2026
|
| View |
|
DRP-10475-06
|
Telmisartan
|
Gomisart-40
|
40 mg
|
Tablet
|
Angiotensin II Receptor Blocker
|
Globela Pharma Private Limited
|
India
|
CLIDP Conversion
|
01 February 2024
|
30 September 2026
|
| View |
|
DRP-10500-01
|
Cefixime (as trihydrate)
|
Speczime
|
100 mg/ 5 mL
|
Granules for Oral Suspension
|
Antibacterial (Cephalosporin)
|
Lloyd Laboratories, Inc
|
Philippines
|
-
|
15 February 2024
|
06 October 2026
|
| View |
|
DRP-10525-01
|
Cefoperazone (as sodium) + Sulbactam (as sodium)
|
Suprazon
|
1 g / 500 mg
|
Powder for Injection (I.M./I.V.)
|
Antibacterial (Cephalosporin)
|
Inject Care Parenterals Pvt. Ltd.
|
India
|
CLIDP Conversion
|
09 February 2024
|
11 October 2026
|
| View |
|
DRP-10747-01
|
Atorvastatin (as calcium)
|
None
|
20 mg
|
Film-Coated Tablet
|
Lipid Modifying Agent (HMG CoA Reductase Inhibitor)
|
Stallion Laboratories Pvt. Ltd
|
India
|
CLIDP Conversion
|
21 February 2024
|
15 November 2026
|
| View |
|
DRP-10748-02
|
Atorvastatin (as calcium)
|
None
|
40 mg
|
Film-Coated Tablet
|
Lipid Modifying Agent (HMG CoA Reductase Inhibitor)
|
Stallion Laboratories Pvt. Ltd.
|
India
|
CLIDP Conversion
|
06 February 2024
|
15 November 2026
|
| View |
DRP-10780-01_PI_01.pdf
|
DRP-10780-01
|
Salbutamol (as sulfate)
|
Asmacaire
|
1 mg/mL (2.5 mg/2.5 mL)
|
Solution for Inhalation
|
Selective Beta-2-adrenoreceptor
|
Axa Parenterals Ltd
|
India
|
CLIDP Conversion
|
06 February 2024
|
17 November 2026
|
| View |
|
DRP-10874-02
|
Ceftriaxone (as sodium) + Sulbactam (as sodium)
|
Kenavactam
|
1 g / 500 mg
|
Powder for Injection (I.M./I.V.)
|
Antibacterial (Cephalosporin – Beta-Lactamase Inhibitor Combination)
|
Theon Pharmaceuticals Limited
|
India
|
CLIDP Conversion
|
20 February 2024
|
10 December 2026
|